Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Verrica Pharmaceuticals aggregated by PharmaCompass.com.

    Client Virtual Booth

    VERRICA PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Verrica Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10 North High Street Suite 200 West Chester, PA 19380
    Telephone
    Telephone
    484-453-3300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://verrica.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/verricapharma
    Twitter
    Twitter
    https://twitter.com/verricapharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Verrica Announces Presentation at the Virtual Healthcare Conference
    Verrica Announces Presentation at the Virtual Healthcare Conference

    https://www.globenewswire.com/news-release/2024/04/02/2855837/0/en/Verrica-Pharmaceuticals-Announces-Presentation-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    Verrica Announces that YCANTH Receives New Chemical Entity Status
    Verrica Announces that YCANTH Receives New Chemical Entity Status

    https://www.globenewswire.com/news-release/2024/03/26/2852256/0/en/Verrica-Pharmaceuticals-Announces-that-YCANTH-Receives-New-Chemical-Entity-Status-and-Orange-Book-Listing-from-the-FDA.html

    GLOBENEWSWIRE
    26 Mar 2024
    Share Share
    Verrica Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
    Verrica Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/29/2837864/0/en/Verrica-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html

    GLOBENEWSWIRE
    29 Feb 2024
    Share Share
    Verrica Announces Participation in TD Cowen 44th Annual Healthcare Conference
    Verrica Announces Participation in TD Cowen 44th Annual Healthcare Conference

    https://www.globenewswire.com//news-release/2024/02/27/2835891/0/en/Verrica-Pharmaceuticals-Announces-Participation-in-the-TD-Cowen-44th-Annual-Healthcare-Conference.html

    GLOBENEWSWIRE
    27 Feb 2024
    Share Share
    Verrica Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results
    Verrica Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/22/2833579/0/en/Verrica-Pharmaceuticals-to-Provide-a-Corporate-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-29-2024.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer
    Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer

    https://www.globenewswire.com//news-release/2024/02/05/2823427/0/en/Verrica-Pharmaceuticals-Files-Lawsuit-Against-Canadian-Drug-Manufacturer-for-False-Advertising-and-Unfair-Competition.html

    GLOBENEWSWIRE
    05 Feb 2024
    Share Share
    Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH
    Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH

    https://www.globenewswire.com/news-release/2024/01/29/2818804/0/en/Verrica-Pharmaceuticals-Receives-Permanent-J-Code-J7354-for-YCANTH-from-Centers-for-Medicare-and-Medicaid-Services.html

    GLOBENEWSWIRE
    29 Jan 2024
    Share Share
    Verrica Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315
    Verrica Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

    https://www.globenewswire.com//news-release/2024/01/05/2804581/0/en/Verrica-Pharmaceuticals-Announces-Last-Patient-Dosed-in-Part-2-of-Phase-2-Study-of-VP-315-a-Potential-First-in-Class-Oncolytic-Peptide-Based-Immunotherapy-for-the-Treatment-of-Basa.html

    GLOBENEWSWIRE
    05 Jan 2024
    Share Share
    Verrica Announces Receipt of Minutes from Type C Meeting Regarding YCANTH
    Verrica Announces Receipt of Minutes from Type C Meeting Regarding YCANTH

    https://www.globenewswire.com//news-release/2024/01/04/2803868/0/en/Verrica-Pharmaceuticals-Announces-Receipt-of-Minutes-from-Type-C-Meeting-with-FDA-Regarding-Clinical-Development-of-YCANTH-for-the-Treatment-of-Common-Warts.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share
    Verrica Announces Specialty Pharmacy Partnership Agreement with Walgreens
    Verrica Announces Specialty Pharmacy Partnership Agreement with Walgreens

    https://www.globenewswire.com//news-release/2024/01/03/2803196/0/en/Verrica-Pharmaceuticals-Announces-Specialty-Pharmacy-Partnership-Agreement-with-Walgreens-to-Distribute-YCANTH.html

    GLOBENEWSWIRE
    03 Jan 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search